The problem

Our team studies the mechanisms underlying chronic liver disease progression to cirrhosis and its complications, with an emphasis on the identification of prognosis markers and therapeutic targets for steatotic liver diseases. Our research program focuses on the identification of immunometabolic targets and biomarkers of liver and systemic inflammation.

The approach

We study the mechanisms underlying monocyte/macrophage reprogramming and the impact on fatty liver disease progression to fibrosis, and on liver regeneration. The role of adaptive immune cells (Th17) and non-conventional T lymphocytes, in particular mucosal-associated invariant T (MAIT) cells, in the control of inflammation at sequential steps of steatotic liver diseases progression and regression.

Main discoveries and innovations

Novel biomarkers and clinical studies evaluating new therapeutic strategies in metabolic dysfunction-associated fatty liver disease (MAFLD), cirrhosis, transplantation and acute-on-chronic liver failure (ACLF), a syndrome we characterized and in which systemic inflammation is a major trigger.


Centre de Recherches sur l’Inflammation, Université Paris Cité, UMR 1149 Inserm, France
Inflammatory and Stress Responses in Chronic Liver Diseases Group, Group Leader

Awards & Honors

International Recognition Award, European Association for the Study of the Liver (EASL)